Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 09:51AM ET
1.52
Dollar change
+0.02
Percentage change
1.67
%
Index- P/E- EPS (ttm)-0.68 Insider Own3.20% Shs Outstand53.98M Perf Week-8.13%
Market Cap82.32M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float52.25M Perf Month-24.88%
Income-31.05M PEG- EPS next Q- Inst Own12.38% Short Float13.11% Perf Quarter-36.19%
Sales0.00M P/S- EPS this Y-28.77% Inst Trans-13.82% Short Ratio21.78 Perf Half Y27.08%
Book/sh0.25 P/B6.03 EPS next Y35.11% ROA-84.76% Short Interest6.85M Perf Year-38.01%
Cash/sh0.06 P/C25.41 EPS next 5Y- ROE-158.25% 52W Range1.04 - 3.23 Perf YTD-43.93%
Dividend Est.- P/FCF- EPS past 5Y17.22% ROI-130.92% 52W High-52.79% Beta1.22
Dividend TTM- Quick Ratio0.78 Sales past 5Y-16.43% Gross Margin- 52W Low46.63% ATR (14)0.13
Dividend Ex-DateAug 28, 1996 Current Ratio1.26 EPS Y/Y TTM20.02% Oper. Margin0.00% RSI (14)31.01 Volatility7.29% 8.48%
Employees- Debt/Eq1.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price8.40
Option/ShortYes / Yes LT Debt/Eq0.88 EPS Q/Q25.07% Payout- Rel Volume0.26 Prev Close1.50
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsFeb 15 BMO Avg Volume314.43K Price1.52
SMA20-12.98% SMA50-26.15% SMA200-23.20% Trades Volume9,161 Change1.67%
Date Action Analyst Rating Change Price Target Change
Jan-13-20Initiated H.C. Wainwright Buy $18
Mar-02-15Initiated Dawson James Buy $3
Mar-19-24 09:00AM
Mar-06-24 08:45AM
Feb-15-24 08:00AM
Feb-14-24 05:11PM
Feb-13-24 12:00PM
08:30AM Loading…
Feb-09-24 08:30AM
Feb-06-24 09:00AM
Jan-31-24 09:00AM
Dec-22-23 08:00AM
Dec-04-23 08:30AM
Nov-20-23 04:15PM
Nov-16-23 08:30AM
Nov-09-23 08:52AM
Oct-30-23 09:20AM
Oct-24-23 08:00AM
09:15AM Loading…
Oct-23-23 09:15AM
Oct-19-23 08:00AM
Oct-09-23 07:50AM
Oct-05-23 08:45AM
Sep-26-23 09:00AM
Aug-11-23 08:07AM
08:00AM
Jul-31-23 05:49AM
Jul-20-23 11:36AM
Jul-17-23 09:23PM
04:05PM
Jul-14-23 09:15AM
Jul-11-23 08:45AM
Jun-22-23 10:19AM
May-16-23 09:17AM
02:18PM Loading…
May-15-23 02:18PM
09:00AM
May-12-23 04:35PM
04:30PM
Apr-27-23 09:12PM
Apr-19-23 09:00AM
Mar-08-23 09:00AM
Mar-03-23 09:00AM
Feb-27-23 05:26AM
Feb-15-23 09:00AM
Jan-03-23 11:57AM
Dec-28-22 09:00AM
Nov-22-22 12:21PM
09:00AM
Oct-17-22 08:50AM
Sep-12-22 09:00AM
Sep-07-22 08:45AM
Aug-24-22 05:45AM
Aug-19-22 08:45AM
Aug-15-22 09:00AM
Aug-08-22 08:45AM
Jul-14-22 10:00AM
Jun-08-22 09:00AM
05:25AM
Jun-07-22 07:30AM
May-27-22 09:00AM
May-19-22 05:10AM
May-16-22 08:50AM
Apr-22-22 09:21AM
Feb-16-22 04:30AM
Feb-14-22 09:00AM
Jan-24-22 02:48PM
Jan-11-22 04:44AM
Dec-22-21 09:00AM
Oct-22-21 08:00AM
Aug-25-21 04:00AM
Aug-16-21 09:00AM
Jul-08-21 12:16PM
Jul-07-21 08:21PM
04:27PM
08:00AM
Jul-06-21 11:16AM
Jul-05-21 10:06PM
Jul-03-21 10:00PM
Jul-02-21 11:20AM
Jun-30-21 09:00AM
06:12AM
Jun-29-21 11:15PM
04:20PM
Jun-28-21 10:34AM
09:46AM
09:20AM
Jun-25-21 08:30AM
Jun-22-21 10:25PM
Jun-17-21 01:09PM
Jun-11-21 11:49AM
Jun-09-21 06:30AM
Jun-08-21 09:03PM
04:37PM
Jun-05-21 06:15AM
May-27-21 02:33PM
May-18-21 09:00AM
Apr-28-21 03:26PM
Apr-15-21 03:41PM
Apr-07-21 03:15AM
Mar-09-21 06:17AM
Mar-01-21 05:15AM
Feb-16-21 09:00AM
Jan-29-21 06:27AM
Jan-28-21 06:21PM
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.